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THE EFFECT OF FDA'S POLICIES ON THE DECREASING EFFECTIVENESS OF
ANTIBIOTICS
A. INTRODUCTION
Over the last century, Americans have seen their life expectancies increase
dramatically from an average age of 47.3 years to an age of 71.5 years for men and
78.3 years for women. Today's two leading causes of death are heart disease and
cancer; whereas, in 1900, the leading causes of death were bacterial diseases such
as pneumonia, inuenza, tuberculosis and diarrhea.1 What is it that has brought
about such tremendous changes in the lives of Americans? Antimicrobial drugs
have played a signicant role. The discovery of antibiotics in the World War II
era and afterwards meant that most bacterial infections could be controlled and
cured. In the ensuing decades, other antimicrobial agents were also developed to
combat certain viral, parasitic and fungal infections. The existing complement
of antimicrobials has made society quickly forget that microbial infection can
be lethal.
This changed when a deadly new disease appeared in the 1980s -
- Acquired Immunodeciency Syndrome (AIDS) { which now threat-
ens to kill an increasing number of Americans each year. AIDS is caused by
the human immunodeciency virus (HIV). This virus destroys the human host's
immune system, thereby making the human
1 Peter Barton Hutt & Richard A. Merrill, Food and Drug Law
867 (2d ed. 1991).
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susceptible to cancer and severe bacterial infections. Although
scientists are frantically trying to develop a cure and physicians are des-
perately trying to treat AIDS patients with the drugs presently available, AIDS
relentlessly continues to kill. The uncontrollable onslaught of this infectious dis-
ease should cause concern not only about the virulence of HIV, but also about
our continued ability to combat infectious disease in general.
The threat of AIDS parallels the bigger threat of uncontrollable bacterial
disease. The many bacterial diseases which in this century became treatable by
antibiotics are once again becoming as uncontrollable and dangerous as AIDS.
The cause
{ microbial drug resistance. Soon after the discovery of antibiotics,
physicians and scientists noticed that bacteria could develop resistance to an
antibiotic by changing their biochemical composition. Likewise is the case with
viruses. Antiviral drugs face an even greater problem of drug resistance because
viruses tend to mutate very quickly and eciently. In addition to these ndings,
scientists have shown that drug resistance can pass from one microbe to another
when the biochemical components which cause drug resistance in one microbe
are transferred to the other microbe. Furthermore, scientists and physicians
now see that bacteria can gain resistance to multiple drugs.2
These days, our society is having trouble treating diseases which used to be
routinely treated with antibiotics. Multi-drug
2 To understand how antibiotic resistance works, see S.B. Levy, The Antibi-
otic Paradox 67-103 (1992).
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resistant tuberculosis has become a serious problem in the United States,
particularly in big cities such as New York City.3 Another excellent exam-
ple of multiple drug resistance can be found among Sta~hvlococcus bacteria
which cause potentially lethal infections such, as Toxic Shock Syndrome. In
1952, Staohvlococcus infections were almost 100 percent curable by penicillin,
whereas, now fewer than 10 percent of such infections can be cured by penicillin.4
Presently, only vancomycin remains as a reliable antibiotic to combat these
infections.5 However, vancomycin too threatens to lose its eectiveness against
Sta~hvlococcus given ndings of vancomycin resistance in other types of bacte-
ria.'
Physicians now have to use higher dosages and dierent antibiotics to rid a
patient of an infection. Furthermore, there are more patients who now become
aicted with bacterial diseases that cannot be combatted by any known antibi-
otic and so the patient dies of the infection. The famous Muppets puppeteer,
Jim Henson, suered such a fate when he became infected with Strevtococcus
~ Jim Henson died of pneumonia { a rare cause of death among otherwise
healthy individuals in this day and age. Henson
~ Id. at 97-98. See also NeQlected Infrastructure Means Uphill Battle Acrainst TB Epidemic,
Health Care Policy Report, Dec. 6, 1993, at 39.
Laurie Garrett, The Coming Plague 411 (1994).
~ Id. at 412.
M.L. Cohen, Epidemiology of Drug Resistance: Implications for a Post-Antimicrobial Era,
257 Science 1050 at 1051 (1992).
Levy, supra note 2 at 134.
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was attacked by a particularly virulent bacterial strain that became uncon-
trollable.
Drug resistance has become a problem in the United States and in the world.
Antibiotics imposed a Darwinian force of natural selection on the microbial
population and so it was inevitable that some resistant microbial strains would
emerge. However, this natural emergence of resistant strains would never have
occurred as quickly were it not for the tremendous amount of antibiotic use
over the last fty years. A serious public health problem has resulted from the
continuous overuse of antibiotics and the slow development of new antibiotics
to replace old ones that have lost their therapeutic value.
This paper will evaluate the eect that the Food and Drug Administration
(FDA) has had on the drug resistance problem and will consider how the FDA
could tailor its regulatory policies to better safeguard the eectiveness of the
American antibiotic supply. The discussion will be divided in two parts. First,
we will look at the consequences of FDA's approach to controlling the dissem-
ination of antibiotics. Secondly, we will examine the eect that FDA policies
have had on the development of new antibiotics. In both parts, we will consider
how the FDA's present approach may be improved upon.
B. FDA'S ROLE IN THE DISSEMINATION OF ANTIBIOTICS
As mentioned earlier, overuse of antibiotics has led to a more
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accelerated decline in antibiotic eectiveness. Antibiotics have
been overused in both human and animal treatment. Physicians and vet-
erinarians both have prescribed antibiotics too often when an antibiotic was
not needed. Furthermore, humans have misused antibiotics by not completing
a prescribed course of antibiotics, or by leaving the antibiotic around and by
using the leftover antibiotics for a later ailment. Antibiotics have also been
overused in subtherapeutic doses in animal feed.
As an agency concerned with the health and safety of Americans, it is
well within the Food and Drug Administration's jurisdiction to control this
widespread use of antibiotics. In this part, we will consider how the FDA has
exercised control over the use of antibiotics. An evaluation of FDA's approach
will be undertaken as well.
1. Introduction to the FDA regulation of drugs
The Food and Drug Administration seeks to protect the health of Americans
against impure and unsafe foods, drugs, cosmetics and other similar hazards.
This important mission is carried out by some 7400 employees using systems of
premarket approval followed by enforcement activities.' Our particular concern
centers around FDA's activities in the area of drugs. The FDA regulates not
only the development of new drugs and their introduction into the marketplace,
but also the sale and marketing of drugs once they are in the marketplace. Both
human and animal drugs are subject to
B
Hutt & Merrill, su~ra note 1 at 16.
5ID# 304|3296|70 6
regulation by the FDA.
The FDA has several tools in its hands to control the use of antibiotics in
both humans and animals. For example, the FDA determines how drugs should
be labeled and what kind of advertising can accompany the sale of drugs. The
FDA also controls the dissemination of drugs. In fact, product labeling is what
led to such controlled dissemination.
In a 1938 regulation which was promulgated shortly after the coming into
force of the Food, Drug, and Cosmetic Act (the Act),' the FDA decided that
those drugs which were labeled as to be used only by or on the prescription
of a physician, dentist or veterinarian could only be sold to a consumer upon
obtaining a prescription from a physician.'0 Hence, the distinction between pre-
scription and over-the-counter drugs was developed.11 In 1951, the regulation
was changed so that the FDA instead of the manufacturer determined what
drugs were to carry prescription status. From that time on, the FDA would
give prescription status to a drug if
its toxicity or other potentiality for harmful eect ... ha[d] been determined
by the Federal Security Administrator, on the basis of opinions generally held
among experts ... to be safe and ecacious for use only after professional
diagnosis.'2
21 U.S.C. x321 et sea.
10 ~ Fed. Reg. 3168 (December 28, 1938).
Peter Temin, The Origin of Compulsory Drug Prescriptions 22
J. L. & Econ. 91 (1979). 12 Id.
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This distinction between prescription and over-the-counter drugs, which was
rst developed through regulation and was not set out in the Act itself until
later,'3 has had a massive eect on the availability of drugs, including antibiotics.
Just as the FDA has limited the sphere of dissemination for human drugs,
the FDA also has the power to control the dissemination of animal drugs used
for therapeutic purposes and as growth promoters in animal feed. This power
comes from a broad reading of the concept of safety as it is used in x512 of
the Act. We will examine FDA regulation of animal drugs more closely a little
later.
2. Controlling the dissemination of antibiotics
Apart from maintaining prescription status for antibiotics, the FDA may
have little authority under the present Act to impose greater controls on the
dissemination of antibiotics. Past case law suggests that, generally, the FDA
cannot interfere with a physician's prescribing of drugs, nor can the FDA restrict
the distribution of drugs.
The FDA's limitations in trying to interfere with a physician's prescribing
practices can be seen in the context of physicians prescribing approved drugs for
unapproved uses. In United States v. Evers, the FDA unsuccessfully challenged
Dr.
13 Section 503(b) of the Food, Drug and Cosmetic Act is the provision that
established the notion of prescription drugs.
643 F.2d 1043 (1981).
7ID# 304|3296|70 8
Evers' unapproved use of Calcium EDTA, an approved drug. Randall
J. found that the prescribing habits of Dr. Evers did not violate the provi-
sions of the Food, Drug, and Cosmetic Act. Given that the FDA was unable to
stop this physician's prescribing practice, it is unlikely that the FDA would be
able to control a physician's prescribing of antibiotics for an unnecessary illness.
In all probability, the FDA would be equally unsuccessful in restricting the
distribution of antibiotics to certain locations. In American Pharmaceutical Association v. Weinbercrer'5,
the Court held that the FDA exceeded its authority when it restricted the dis-
tribution of methadone to (a) approved maintenance treatment programs, (b)
approved hospital pharmacies, and (c) in cases where hospital pharmacies were
unavailable in a particular area, to selected community pharmacies. The Court
decided that limited distribution of such a drug could be determined solely by
the Justice Department.
Due to the prevalent use of antibiotics in genuine cases of microbial infection,
it is questionable whether imposing further controls on physician prescribing or
on drug distribution would even be a good idea. Such measures may severely
sacrice the short-term needs of a sick patient suering from a microbial in-
fection for the longer term public health concerns. On balance, it seems that
proper physician training combined with continued prescription status of an-
tibiotic drugs is the best regulatory strategy which is available to the FDA to
control antibiotic
377 F.Supp. 824 (1974).
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dissemination.
Despite the seemingly obvious need to maintain control over antimicrobial
drug use so as to prevent further decline in the eectiveness of the antimicrobial
drug supply, the FDA has become increasingly keen about the idea of switching
certain drugs, including antimicrobial drugs, from prescription (Rx) status to
over-the-counter (OTC) status. In fact, antibiotic rst aid creams already have
OTC status. Recently, there has been consideration about whether to switch
Zovirax (or acyclovir) from prescription status to OTC status. Zovirax is an an-
tiviral drug that is used in the treatment of genital herpes. In deciding whether
to switch the status of Zovirax, drug resistance is the
'7
main concern. Topical erythromycin for acne treatment has also been con-
sidered as an appropriate candidate for a Rx-OTC switch.
Prescription drugs can be switched to over-the-counter status in three ways.
First, the holder of a new drug application (NDA) can submit a supplemental
application requesting such a switch in status. Second, the manufacturer of the
drug or any other person can petition for such a switch pursuant to 21 C.F.R.
par. 310.200. Thirdly, a switch can be made following an internal FDA review
of
Updates, FDA Rules on OTC Antibiotics, FDA Consumer, March 1988, at
2.
'7
Zovirax OTC Switch Advisory Committee Review Expected in Late 1994 or Early 1995,
FDC Reports, The Pink Sheet, July 4, 1994, T&G-1-T&G-2.
'~ Topical Erythromycin. Retin-A for Acne Are Logical Rx to OTC Switch Candidates. Dermatologist Tells NDMA,
FDC Reports, The Pink Sheet, Sept. 1, 1992, at 11-12.
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the matter. These internal reviews are carried out using the OTC Drug
Review process. Normally, the FDA considers the following factors in deciding
whether or not to authorize a switch: (1) the toxicity of the drug; (2) the
potentiality for harmful eect; (3) the method of use or collateral measures
necessary to use; and (4) broad issues of social policy.
There are two main arguments that are made for the need to switch the
status of antimicrobial drugs. First, such a switch would make the cost of
treating an infection much lower. The consumer requiring a drug would not have
to pay a dispensing fee or the fee of a visit to a doctor. Insurance companies
would be happy indeed with the lower costs associated with such a system.
Secondly, in the cases of drugs such as Zovirax which treat illnesses that are often
embarrassing, the patient would be able to obtain treatment without having to
undergo the humiliation of discussing the matter at the doctor's oce.
However, given the drug resistance problem, these arguments for switching
the status of certain antimicrobial drugs are not suciently convincing. In all
likelihood, self-medicating patients would end up misusing and overusing the
drugs even more than they are doing today. This is certainly the trend in those
countries where antibiotics can be obtained without a prescription.20 Over-the-
counter availability of antimicrobial
19
See P.B. Hutt, A Legal Framework for Future Decisions on Transferring Drugs from Prescription to Nonprescription Status,
37 Food Drug Cosm. L.J. 427 (1982).
20 Levy, supra note 2 at 107|14, 231|34.
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drugs would lead to an even more rapid decline in the potency of our antimi-
crobial drug supply. The consequences could be disastrous. The cost savings in
switching the status of antimicrobial drugs to over-the-counter status would be
eliminated if those drugs lost their eectiveness in combatting disease. Treating
infections caused by resistant strains is already incredibly expensive. The whole
problem of drug resistance has
added $100 to $200 million a year to the United States' health care
21
costs. Therefore, for public policy reasons, prescription status
must be maintained for antimicrobial drugs.
2. Controlling the use of antibiotics using balanced advertising and complete labeling of antibiotic Products
There is no doubt that by maintaining prescription status for antibiotics,
the FDA has limited their use. However, the system is not foolproof. Overuse
is still a problem in this country. Physicians, who of all people should be aware
of the drug resistance problem, often overprescribe antibiotics. This occurs for
several reasons. First, physicians are often severely
pressured by their patients to prescribe an antibiotic for any
22
ailment. Second, physicians prescribe broad spectrum antibiotics
21
Ann Gibbon, Exploring New Strategies to Fight Drug-Resistant Microbes,
257 Science 1036 at 1036 (1992). Furthermore, treating one patient who has con-
tracted multi-drug resistant tuberculosis can cost more than $100,000. California County Ocials Resort To Arrests in TB Treatment Crackdown,
Health Care Policy Report, Nov. 28, 1994, at 47.
22
Levy, supra note 2 at 105-107, 210-11.
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when a narrow spectrum antibiotic would do.23 Thirdly, physicians
may prescribe too large or too small a dose of antibiotic to cure the infection
in question.24 Finally, the physician may get confused about which antibiotic to
prescribe due to all the products on the market.25 Patients also tend to misuse
antibiotics by self-medicating with old antibiotics that remained in the medicine
cabinet from a previous illness.2' If physicians continue to be too lenient in their
prescribing habits and patients continue to misuse drugs, using prescription drug
status as a means of controlling antibiotic dissemination will be insucient as
a tool to oset a drug resistance crisis.
One way to induce proper behavior in both physicians and patients is through
education. Because pharmaceutical companies know the most about the antibi-
otics they sell, physicians tend to
rely heavily on the information provided by these companies about
27
their products. Many authors have commented that the information pro-
vided by pharmaceutical companies is incomplete and misleading
and that this often results in improper antibiotic use.2' Most
23 Gibbon, su~ra note 21 at 1038.
24 Levy, supra note 2 at 227-28, 234|36.
25 Stephen Ackerman, Today's New Breed of Antibiotics, FDA Consumer,
Dec/Jan. 1988, at 22.
26 Levy, supra note 2 at 211-14.
27 Garrett, supra note 4 at 681 n. 125.
26 Stephen Ackerman, Today's New Breed of Antibiotics, FDA
Consumer, Dec/Jan. 1988, at 22; Jerey A. Fisher, The Plague
Makers 139-50, 159 (1994); Stuart B. Levy, The Antibiotic Paradox
237 (1992).
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patients have obtained little or no education regarding the proper use of
antibiotics and so this population still tends to think, albeit inaccurately, that
an antibiotic is a miracle drug that is needed for everything, including all colds.2'
The FDA seeks to educate the public, including physicians, by imposing
advertising and labeling requirements on pharmaceutical companies. These re-
quirements are dierent for physicians and for patients. Prescription drug ad-
vertising to professionals is governed by a federal regulation that dictates that
advertising must not be false, lacking in fair balance or otherwise misleading.30
Similar requirements are imposed on direct-to-consumer advertising of prescrip-
tion drugs. The FDA has also established physician labeling regulations spec-
ifying the format and content of a professional package insert for all human
prescription drugs.3' As for patients, drug labeling is specied in x502 of the
Act. However, prescription drugs are exempted from some aspects of these
requirements in ~503(2). A prescription drug label must only contain the fol-
lowing:
[T]he name and address of the dispenser, the serial number and date of the
prescription or of its lling, the name of the prescriber, and, if stated in the
prescription, the name of the patient, and the directions for use and cautionary
statements, if any, contained in such prescription.32
Levy, supra note 2 at 208-14.
3021 C.F.R. x202.1(6)|(7).
21 C.F.R. 201.56 and 201.57.
32 Id.
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These provisions are supposed to ensure that the information being provided
by pharmaceutical companies is balanced and accurate.
Despite these rules, both physicians and patients remain uninformed about
proper antibiotic use. The FDA should review the current labeling and advertis-
ing requirements for antibiotics. Imposing more stringent labeling and advertis-
ing requirements on antibiotics regarding their proper use and their side eects
would be one way to encourage proper use of antibiotics. Both physicians and
patients must obtain more information about how their activities exacerbate the
increasing drug resistance problem. This kind of information should be provided
to the physician in the physician package insert and to the patient in the form
of a patient package insert. Physicians must be given more information about
the appropriateness of certain antibiotics to treat certain illnesses. Patients, on
the other hand, must be told not to reuse old antibiotics nor to use antibiotics
unless a bacterial infection is plaguing them.
4. Use of Antibiotics in Animal Feed
The same concerns as the ones raised above arise when considering the ther-
apeutic use of antibiotics in animals. In the case of animals, the FDA has
taken specic steps to limit the use of prescription drugs such as antibiotics.
In a 1988 regulation, the FDA created the distinction between prescription and
over-thecounter animal drugs.33 These regulations have been upheld in the
Hutt & Merrill, supra note 1 at 655.
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courts as being a valid interpretation of the statutory requirement in ~.
502(f)(l) for adequate directions for use.3' Under those regulations, it is also
generally unlawful for a veterinarian to prescribe a drug for an unapproved use.
In extreme cases, extra-label use may be allowed. This additional limitation on
the therapeutic use of antibiotics in animals is a wise decision of the FDA since
it helps control the drug resistance problem.
However, the bigger concern with respect to antibiotic use in animals is the
widespread subtherapeutic use of putting antibiotics in animal feed. Farm ani-
mals receive nearly half of all the antibiotics produced in the United States. In
1972, an FDA Task Force on the Use of Antibiotics in Animal Feeds came to
the conclusion that antibiotic use in animal feed had to be limited to control
the numbers of drug resistant micro-organisms. Upon the Task Force's recom-
mendation, a new provision was inserted in the FDA Regulations which limits
subtherapeutic use of antibiotics to those antibiotics which are not used in hu-
man treatment.3' The regulation was particularly aimed at the use of penicillin
and tetracycline in animal feed. This action produced a tremendous outcry from
the industry and, to this day, the regulation is not enforced and antibiotics in
animal feed continue to be used.
The following events led to this situation. Following FDA's
~' United States v. Colahan, 635 F.2d 564 (6th Cir. 1980).
Food and Drug Administration, Compliance Policy Guide 7125.06 (Nov. 1,
1986).
36 See 21 C.F.R. x558.15.
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announcement of its proposed regulations, the House Appropriations Com-
mittee instructed FDA to delay regulatory action against the use of antibiotics
in animal feed pending a study of the matter by the National Academy of Sci-
ences (NAS). The NAS concluded that further studies had to be done to resolve
the issue.36 The House Appropriations Committee then instructed the FDA to
conduct these further studies. Meanwhile, in February 1983, the FDA agreed to
continue approving new uses and new combinations of antibiotics pending the
outcome of the studies.39 In 1989, the NAS completed the additional studies
and reported that it was unable to nd direct scientic proof of a link between
human illness and subtherapeutic use of antimicrobials in animal feed. The NAS
again recommended further studies which could be undertaken to establish such
direct scientic proof.'0
Experts are frustrated that the debate surrounding antibiotics in animal feed
has continued for fteen years and yet has yielded
4'
few results. Despite the absence of direct proof that antibiotics in animal
feed exacerbate the drug resistance problem,
Hutt & Merrill, supra note 1 at 652|53.
36 National Academy of Sciences, The Eects on Human Health of Subther-
apeutic Use of Antimicrobials in Animal Feed (1980).
48 Fed. Reg. 4490 and 4554 (February 1, 1983).
40 Institute of Medicine of the National Academy of Sciences, Human Health
Risks with the Subtherapeutic Use of Penicillin or Tetracycline in Animal Feed
(1988).
41
Karen Wright, The Policy Response: In Limbo, 249 Science
24 at 24 (1990).
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many experts continue to claim that there is a denite link.'2 According to
Levy, a leading expert in the antibiotic drug resistance eld, the extensive use
of antibiotics in animal feed has imposed a tremendous selective pressure on
resistant organisms to breed in the intestinal tracts of animals. These resistant
organisms get passed on to humans in several ways. First, farmers come in
contact with these resistant organisms directly. Secondly, consumers come in
contact with these organisms through animal meat. Thirdly, if fecal material of
such animals is used as a fertilizer to grow vegetables, these organisms can be
harbored in the plants we eat. These various modes of transmission have been
illustrated through scientic studies.
In the case of regulating the use of antimicrobials in animal feed, the FDA is
faced with the classic dilemma of how to regulate in the face of uncertainty. The
FDA should restrict the use of antibiotics in animal feed despite absolute cer-
tainty. The opinion of leading experts should be heeded, especially when society
is facing such a serious public health concern, namely, the decreasing eective-
ness of antibiotics to treat infection. From a costbenef it point of view, the
amount that society stands to lose if antibiotics lose their eectiveness greatly
exceeds the gains of an increased growth rate in animals. This is particularly
true given that: (1) more and more antibiotic must be given to promote growth
and (2) even with these higher doses, the growth promotion
42 See, for example, Levy, supra note 2 at 137-156.
Id.
17ID# 304|3296|70 18
eect is not nearly as great as it was twenty years ago.
The FDA must impose more stringent controls on the use of antibiotics
in animal feed. A straight ban on antibiotic use in animal feed may be too
drastic a measure since such a measure might have serious eects on the quality
and quantity of the food we eat. However, strict use of antibiotics in animal
feed is essential to preserve the eectiveness of presently available antibiotics.
Ultimately, determining the extent to which antibiotic use should be controlled
involves the broad question of how best to ensure the health and safety of the
American public. On the one hand, the food supply must be safe and nourishing.
On the other hand, the drug supply must be safe and eective. The solution
must balance these two concerns. The FDA should at least ban the use in
animal feed of those antibiotics that are used in human therapy. This would
prevent animals from passing on organisms to humans that are resistant to
human antibiotics. It would also reduce the selective pressure being imposed on
dangerous human pathogens.
C. FDA'S ROLE IN THE DEVELOPMENT OF NEW ANTIBI-
OTICS
The FDA must adopt a two-part strategy to ensure that the American pop-
ulation has an eective drug supply which can control
Id. at 142.
This policy has been adopted in Canada, England and other European
countries. Levy, supra note 2 at 142.
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the onset of infectious diseases. In part B of this paper, we
considered what the FDA was doing and what it could do in addition to safe-
guard the eectiveness of the antibiotics presently available. Several strategies
were identied, including, controlling and restricting the use of antibiotics, and
educating the public about proper antibiotic use. However, because drug resis-
tant organisms already exist in great numbers and because they will continue
to develop through the process of natural selection, the FDA must promote a
second strategy to combat drug resistance. The FDA must strongly encourage
the development of new antibiotics. Promoting such development requires an
FDA new drug approval system that is relatively ecient and that does not
discourage manufacturers from developing new antibiotics.
1. The FDA aPvroval system for new drugs and antibiotics
Although a read through x~505 and 507 of the Food, Drug, and Cosmetic Act
of 1962 suggests that the FDA deals with new antibiotics dierently from other
new drugs, subsequent regulations eectively have removed the distinction. For
example, antibiotics are now subject to the same investigational new drug
(IND) and new drug application (NDA) requirements as other new
46
drugs. Furthermore, due to the high level of manufacturer compliance with
antibiotic standards, FDA has exempted all classes
of antibiotics from batch certication as required by ~507 of the
21 C.F.R. Parts 312-314.
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Act.'7 With these changes, antibiotics are now regulated in virtually the
same manner as other new drugs.
In order to market a new antibiotic, a manufacturer must rst obtain FDA
approval of an NDA. The FDA evaluates the NDA on the basis of safety and
eectiveness standards. Before submitting the NDA, the manufacturer must
have conducted preclinical animal studies and clinical human studies to deter-
mine whether the new drug is safe and eective. The clinical research stage
involves three phases and requires the ling of an IND application before the
clinical research commences. Generally, under the IND, only those patients
involved in the study have access to the drug. All the data gained from this
preclinical and clinical testing must be included in the NDA which is submit-
ted to the FDA for review and approval. The time elapsed between preclinical
testing and nal approval by the FDA of an NDA can be anywhere between
7 and 13 years. As can be seen, the FDA maintains the quality of the Amer-
ican drug supply but, as a result, the process of bringing new drugs into the
market is incredibly expensive and time consuming. The requirements for the
NDA are onerous and detailed. Each NDA consists of about 2 to 15 volumes of
summary material accompanied by about 10 to 100 volumes (occasionally up
to 400 volumes 100,000
'~ See 47 Fed. Reg. 19954 (May 7, 1982), 47 Fed. Reg. 39155 (September
7, 1982), codied in 21 C.F.R. x 433.1.
48 Hutt & Merrill, supra note 1 at 514.
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to 200,000 pages) of raw data.'9
The FDA has accorded expedited consideration to some new drug appli-
cations. This has usually been done for important new medicines. The FDA
has taken eorts to accelerate the approval of important new drugs in two ways.
First, the FDA has established a triage system whereby the important new drugs
get priority in being reviewed.50 Secondly, in the cases of important new drugs,
biological products and antibiotics developed for life-threatening and severely
debilitating diseases, the FDA has issued a new rule to streamline the NDA
process.5' The entire expedited approach set out in the rule was based on the
procedure used to approve a new AIDS drug called Zidovudine (also known
as AZT). The whole approval process for Zidovudine ended up being only two
years as opposed to eight years.
Under the new rule, the FDA notes that it will increase its consultations
with the drug manufacturer throughout the NDA approval process. The FDA
also agrees to reduce, in some cases, the number of clinical trials that have to
be done to get approval. Finally, the FDA notes that it may make approval
conditional on an
The Food and Drug Administration's Process for Approving New
Drugs, Report of the Subcommittee on Science, Research and
Technology of the House Committee on Science and Technology, 96th
Cong., 2nd Sess. (1980).
Food and Drug Administration, Sta Manual Guide BD4820.3., as repro-
duced in Hutt & Merrill, supra note 1 at 529.
51 Investigational new drug, antibiotic, and biological drug product reg-
ulations: procedures for drugs intended to treat lifethreatening and severely
debilitating illnesses, 53 Fed. Reg. 41516 (1988).
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agreement with the manufacturer to conduct further post-marketing stud-
ies regarding the safety and ecacy of the drug. Requiring additional post-
marketing studies to expedite drug approval is not a novel idea. It was required
by the FDA prior to the issuance of this regulation in the case of Levodopa, a
new drug that was developed for the treatment of Parkinson's Disease.52
The FDA also allows investigational new drugs to be used in the treatment
of life-threatening conditions even when the sick individual is not involved in a
clinical study. Prior to the development of AIDS, emergency INDs and compas-
sionate INDs were granted for this purpose on a case-by-case basis. With the
onset of AIDS, treatment INDs were created so that a larger population could
be treated by an unapproved new drug undergoing approval. These INDs are
called Treatment INDs and may be granted under the following conditions:
(i) the drug may be eective for its intended use in its intended
patient population;
(ii) the drug would not expose the patients to whom the drug is to be
administered to an unreasonable and signicant additional risk of illness or
injury;
(iii) the sale does not constitute commercial marketing of a new drug for
which a marketing application has not been approved;
(iv) the drug is not being commercially promoted or advertised; and
52 Nancy Mattison & Barbara W. Richard, Postapproval Research
Reguested by the FDA at the Time of NCE A~~roval 1970-1984, 21 Drug In-
formation Journal 309 (1987).
Hutt & Merrill, supra note 1 at 553|54.
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(v) the sponsor of the drug is actively pursuing marketing approval
with due diligence).5'
The FDA has agreed to allow companies to charge for drugs used by patients
pursuant to the treatment IND in order to recoup their costs but has prohib-
ited commercial marketing of the drug.55 Although these treatment INDs are
mostly for the benet of patients, the system can also be benecial for the drug
manufacturers. The wider use of the drug can quickly reveal signicant benets
and risks which dictate whether a continued investment in the development of
the drug is warranted.
2. Tailoring FDA policy to accommodate current trends in antibiotic development
Until the 1980s, pharmaceutical companies were actively developing new
antibiotics and so antibiotics always stayed a step ahead in the race against the
microbes. ~' However, in the 1980s, further development became uneconomical
and numerous drug companies abandoned research into new antibiotics. Only
nine new antibiotics were approved in 1992 and 1993 by the FDA.57 Despite the
increasingly serious problem of drug resistance, pharmaceutical
Investigational New Drug, Antibiotic, and Biological Drug Product Regula-
tions: Treatment Use and Sale, 52 Fed. Reg. 19466 (1987).
~ Id.
~ Gibbon, su~ra note 21 at 1036.
~ Elizabeth Culotta, Funding Crunch Hobbles Antibiotic Resistance Research,
264 Science 362 at 363 (1994).
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companies have remained relatively inactive in the area of
antibiotic research.
A further problem with the few antibiotics introduced in 1992 and 1993
is that none of these antibiotics introduced any new operating mechanism for
combatting infection.5' Similarity in operating mechanism is, in fact, a weakness
of all the antibiotics in existence. Although there are 160 antibiotics on the
market, there are only 15 variations in the mechanisms used.5' This lack of
variability in the mechanism of antibiotics makes our drug supply even more
weak in the face of attack from drug-resistant microorganisms.
The few large pharmaceutical companies that have continued antibiotic re-
search have simply tried to manipulate those antibiotic compounds that have
already been developed.'0 This is problematic since some scientists believe that
companies have gone as far as they can with this strategy. The companies that
are engaging in the most innovative research are the small biotechnology com-
panies. These companies are exploring entirely new ways of attacking microbes.
Some of these biotechnology companies are even trying to develop vaccines to
stave o the most drug-resistant bacteria such as Sta~hvlococcus aureus. Vac-
cines
Id.
Gene Bylinsky, The New Fight Against Killer Microbes, Fortune, Sept. 5,
1994, 74 at 76.
Id.
John Travis, Reviving the Antibiotic Miracle?, 264 Science 360 (1994).
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are seen by experts as being one of the best way of conquering microbes
because they prevent infection. By using the body's immune system to prevent
disease, vaccines don't have resistance problems 62
Although it is encouraging that small companies are engaging in antibiotic
research, the concern is that they will not be successful in ultimately marketing
a new antibiotic because of the tremendous costs involved. The estimated cost
of bringing a new antibiotic agent to the market is $300 million dollars.'3 When
examining costs, the length of the approval process must also be considered.
Not only may a small company have a hard time waiting ten years to obtain
a marketable product, but so will society who will be faced with an increasing
drug resistance problem. These concerns suggest that rather than safeguarding
the health of Americans, the FDA may in fact hinder it by discouraging the
development of new antibiotics. A streamlined NDA approval system is needed
in this area. This approval system must be shortened without unduly sacric-
ing the FDA's policy that only new drugs that are safe and eective can be
marketed.
The regulation that allows for expedited approval of lifesaving new antibi-
otics is obviously a step in the right direction.
62
For more information about the research presently being
undertaken by these biotechnology companies: (1) Gene Bylinsky,
The New Fight Against Killer Microbes, Fortune, Sept. 5, 1994, at
74; (2) Joan OC. Hamilton, Who Will Stop the Mutant Microbes?,
Business Week, Aug. 1, 1994, at 52; and John Rennie, No Snake Oil
Here, Scientic American, March 1993, at 136.
'~ Barbara E. Murray, Can Antibiotic Resistance Be Controlled?, 330 N.E.J.M.
1229 at 1230 (1994).
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However, the problem is determining what antibiotics would actually be
classied as being for the treatment of life-threatening and debilitating dis-
eases. The requirement could be interpreted very broadly and very narrowly.
If the applicability of the regulation were interpreted very narrowly, then pre-
sumably only a certain number of antibiotics might be considered eligible for
expedited approval. Perhaps only those new antibiotics that could ght multiple
drug-resistant strains would be included. The problem is that many microbial
infections are life-threatening or severely debilitating if the individual fails to re-
ceive eective antimicrobial treatment. Furthermore, new antibiotics that could
be useful against single drug-resistant microbes could be equally important to
patients who are allergic to the alternative existing antibiotics.
At least two steps should be taken by the FDA in the area of new drug
approvals. First, the scope of the new expedited approval process should be
clearly ascertained as regards antibiotics. It has been suggested that the FDA
has promised to expedite promising antibiotics through this process. If this
means that all antibiotics will be given priority in consideration then no sepa-
rate expedited approval process needs to be set up under the Food, Drug, and
Cosmetic Act. Secondly, the FDA should consider establishing an expedited
licensing process for new vaccines that may be introduced to combat infectious
diseases in the future. Although this expedited licensing process would be un-
dertaken under
64
See Bylinsky and Hamilton, su~ra note 62.
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the Biologics Act, its elements could be very similar to the elements seen in
the expedited approval process set up under the
Food, Drug and Cosmetic Act. By ensuring that both new antibiotics and
vaccines are being approved quickly, the FDA could be instrumental in avoiding
an acute drug resistance crisis.
D. CONCLUSION
There is reason to be concerned about the rising number of drug resistant
microbes and the decreasing number of eective antibiotics. It is hard to imagine
that a post-antibiotic era could come in which society would revert back to
what it was before penicillin was discovered in the 1930s. Because it is within
the FDA's jurisdiction to control the American drug supply, it is important to
analyze what the FDA is doing to alleviate an antibiotic drug crisis and what
it could do in addition. A study of the FDA's activities suggests that there is
room for improvement in the FDA's approach.
42 U.S.C. x262. For historic reasons, biological products, including vaccines,
are regulated under the Biologics Act instead of the Food, Drug, and Cosmetic
Act. Dierent requirements are imposed on biologic producers as opposed to
new drug and antibiotic producers before marketing can occur. Unlike produc-
ers of new drugs and antibiotics, producers of biologics must obtain separate
licenses both for the manufacturing plant and for each individual product to
be manufactured at the plant. Normally, the FDA requires clinical testing of
a biologic being produced at a new location before it will license production
of the biologic there. See Hutt & Merrill, su~ra note 1 at 664-65. Despite
these dierences, both antibiotics and vaccines have to undergo lengthy and
costly pre-marketing reviews. Therefore, expedited approval is warranted in
both cases.
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The FDA must have a two-part strategy for dealing with the drug resistance
problem. First, the FDA must safeguard the eectiveness of the antibiotics
presently on the market. This means that the FDA should: (1) avoid switching
antibiotics from prescription to non-prescription status; (2) better educate both
physicians and patients about the proper use of antibiotics by imposing more
stringent labeling requirements; and (3) ban the use of human antibiotics in
animal feed. Secondly, the FDA must encourage rather than hinder the rapid
development of new antibiotics and vaccines. Antibiotic and vaccine develop-
ment could be greatly assisted by expediting the approval of these compounds.
Although the FDA could safeguard the eectiveness of the American drug
supply by adopting all of these policies, it must be realized that drug resistance
is a global problem. Other countries of the world are also facing drug resistance
problems that are reaching crisis levels in developing countries. Ultimately,
combatting drug resistance must be done on a worldwide scale. Nevertheless, the
FDA must begin addressing the problem at least from the American perspective.
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For more information about the global drug resistance problem, see Levy,
supra note 2 at 223-53, and Garrett, su~ra note
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